Autologous serum application in the treatment of neurotrophic keratopathy
- PMID: 15177961
- DOI: 10.1016/j.ophtha.2003.10.019
Autologous serum application in the treatment of neurotrophic keratopathy
Abstract
Objective: To evaluate the effect of autologous serum application for epithelial disorders in neurotrophic keratopathy (NK).
Design: Retrospective, noncomparative case series.
Participants: Fourteen eyes of 11 patients with NK seen at Tokyo Dental College, Ichikawa General Hospital, Department of Ophthalmology, were studied.
Intervention: Twenty percent topical autologous serum eye drops were applied 5 to 10 times daily until resolution of the NK. Patients underwent routine ophthalmic examinations, including slit-lamp examination, corneal fluorescein dye testing, Cochet-Bonnet corneal sensitivity (Luneau, France), and best-corrected visual acuity (BCVA) measurements before and at the end of the treatment. Moreover, serum samples from 10 healthy volunteers were studied for the levels of substance P (SP), insulinlike growth factor (IGF-1), and nerve growth factor (NGF) by using radioimmunoassay and enzyme-linked immunosorbent assay techniques. Tear samples from 3 healthy subjects also were analyzed for NGF and IGF-1 levels by the same techniques.
Main outcome measures: The changes in corneal disease state, corneal sensitivity, and BCVA with treatment were evaluated. The levels of neural healing factors like SP, IGF-1, and NGF in serum as well as NGF and IGF-1 in tears of healthy subjects also were examined.
Results: The epithelial disorders healed completely in all eyes within 6 to 32 days (mean, 17.1+/-8.0 days), with a decrease in corneal scarring. The mean pretreatment corneal sensitivity was 11.8+/-11.6 mm, which increased to 30.0+/-22.9 mm after treatment at the last follow-up. Five eyes attained normal corneal sensitivity with treatment. The BCVA improved by >2 Landolt lines in 78.6% of the eyes. The mean concentrations of SP in diluted and undiluted serum were 31.4+/-8.4 pg/ml and 157.0+/-42.1 pg/ml, respectively. The mean respective concentrations of IGF-1 in diluted and undiluted serum were 31.4+/-14.8 ng/ml and 157.0+/-73.9 ng/ml. The mean concentrations for NGF were 93.6+/-63.5 pg/ml and 468.3+/-317.4 pg/ml in serum samples with and without dilution, respectively. The mean concentration of NGF in tears was found to be 54 pg/ml. Insulinlike growth factor 1 was not detected in tears in this study.
Conclusions: Autologous serum harbors neurotrophic factors. Autologous serum treatment may provide neural healers to the compromised ocular surface and seems promising for the restoration of the ocular surface epithelial integrity in patients with NK.
Similar articles
-
Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis.Ophthalmology. 2007 Sep;114(9):1637-42. doi: 10.1016/j.ophtha.2006.12.014. Epub 2007 Mar 26. Ophthalmology. 2007. PMID: 17382396
-
Autologous serum eyedrops in the treatment of aniridic keratopathy.Ophthalmology. 2008 Feb;115(2):262-7. doi: 10.1016/j.ophtha.2007.03.087. Epub 2007 Aug 6. Ophthalmology. 2008. PMID: 17675158
-
Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy.Br J Ophthalmol. 2008 Jul;92(7):896-900. doi: 10.1136/bjo.2007.130013. Epub 2008 May 29. Br J Ophthalmol. 2008. PMID: 18511539 Clinical Trial.
-
[Neurotrophic keratopathy--studies on substance P and the clinical significance of corneal sensation].Nippon Ganka Gakkai Zasshi. 1997 Dec;101(12):948-74. Nippon Ganka Gakkai Zasshi. 1997. PMID: 9436358 Review. Japanese.
-
Ocular surface findings in Hallopeau-Siemens subtype of dystrophic epidermolysis bullosa: report of a case and literature review.Cornea. 2005 May;24(4):474-9. doi: 10.1097/01.ico.0000151722.84634.bf. Cornea. 2005. PMID: 15829808 Review.
Cited by
-
Evaluation of the Use of Highly Concentrated Autologous Platelet-Rich Plasma and Platelet-Rich Fibrin Membrane to Improve the Outcome in the Management of Severe Dry Eye Disease, Corneal Neurotrophic Ulcer and Corneal Burn.Cureus. 2024 Jan 7;16(1):e51794. doi: 10.7759/cureus.51794. eCollection 2024 Jan. Cureus. 2024. PMID: 38322082 Free PMC article.
-
Development of In Vitro Dry Eye Models to Study Proliferative and Anti-Inflammatory Effects of Allogeneic Serum Eye Drops.Int J Mol Sci. 2023 Jan 13;24(2):1567. doi: 10.3390/ijms24021567. Int J Mol Sci. 2023. PMID: 36675083 Free PMC article.
-
Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2623-2637. doi: 10.1007/s00417-022-05602-z. Epub 2022 Mar 7. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35254511
-
Neuropathic Corneal Pain: Approaches for Management.Ophthalmology. 2017 Nov;124(11S):S34-S47. doi: 10.1016/j.ophtha.2017.08.004. Ophthalmology. 2017. PMID: 29055360 Free PMC article. Review.
-
Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments.Pharmaceuticals (Basel). 2025 Jul 2;18(7):994. doi: 10.3390/ph18070994. Pharmaceuticals (Basel). 2025. PMID: 40732283 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous